Vaxart, Inc. cash flow to debt ratio of 85.85% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Vaxart, Inc.'s free cash flow has increased -116.70% from $-45.32M last year to $7.57M, signaling increasing performance

Vaxart, Inc.'s debt to equity ratio is 0.08, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Vaxart, Inc.'s debt has decreased relative to shareholder equity from 0.40 last year to 0.08 today, signaling strengthened financials

Vaxart, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Vaxart, Inc.'s interest coverage ratio of 16.38 indicates that earnings with good margin can cover interest payments on company debt

Vaxart, Inc.'s profit margin has increased (-106.22%) in the last year from -233.27% to 14.51%, signaling increasing performance

Vaxart, Inc.'s short-term assets of $136.12M exceed its short-term liabilities of $86.75M

Vaxart, Inc.'s return on assets of 20.60% is higher than the 5.00% threshold, indicating efficient asset utilization

Vaxart, Inc.'s return on equity of 61.43%, is higher than 15.00%, indicating good performance

Vaxart, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Vaxart, Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings

Vaxart, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Vaxart, Inc. has a free cash flow yield of 5.69%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Vaxart, Inc.'s yearly earnings has increased -124.39% since last year from $-66.95M to $16.33M, signaling increasing performance

Vaxart, Inc.'s yearly revenue has increased 726.68% since last year from $28.70M to $237.26M, signaling increasing performance

ROIC 35.71% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Vaxart, Inc.'s 3-year revenue CAGR of 1.20K% is positive, indicating growing revenue over the past 3 years

Vaxart, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Vaxart, Inc. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity

Vaxart, Inc. has insufficient data to evaluate this check.

Vaxart, Inc. has an earnings yield of 28.04%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Vaxart, Inc. is undervalued relative to its fair value price of 1.01 based on EBITDA multiple model

Vaxart, Inc. has an EV/EBITDA ratio of 3.13x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Vaxart, Inc. is overvalued relative to its fair value price of -225.18 based on Earnings Fair Value model

Vaxart, Inc. has a PEG-ratio under 1 which is considered undervalued

Vaxart, Inc. has a price-to-book ratio of 1.41x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Vaxart, Inc. has a price-to-sales ratio of 0.52x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue